Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
REI.....TELL.....VLD.....MULN......https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=VLD&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=TELL&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=REI&p=W&b=5&g=0&id=p84354014936
$STLNF Stallion Uranium completes extensive geophysical survey on ATHA Energy joint venture property
It covered more than 2,200 square kilometres of ground, revealing over 560 kilometres of conductive trends https://mugglehead.com/stallion-uranium-completes-extensive-geophysical-survey-on-atha-energy-joint-venture-property/
#FUBO Netflix Buyout , could send fubotv skyrocketing $$$$
$TWOH, DEBT FREE AND READY TO MINGLE… https://www.reddit.com/r/10xPennyStocks/comments/1bfgfk5/twoh_debt_free_and_ready_to_mingle/
Ladybug $LBRG Targets Growth with Acquisition of Two E-Commerce Sites, Anticipating $4M+ Annual Revenue Boost https://finance.yahoo.com/news/ladybug-targets-growth-acquisition-two-111500876.html
$STLNF Stallion Uranium Announces Additional Uranium Property Staking, Further Expanding Largest Exploration Land Package in Southwestern Athabasca Basin https://finance.yahoo.com/news/stallion-uranium-announces-additional-uranium-113000019.html
$TWOH STRATEGIC EXPANSION UNVEILED: HOW THE TWOH ACQUISITION PLAYBOOK WILL TRANSFORM FOOD DISTRIBUTION IN CANADA https://twohandsgroup.com/blog/strategic-expansion-twoh-acquisition-playbook
$STLNF NEWS — CEO.CA Presents PDAC Recap: Exclusive Interviews From Mining Leaders https://finance.yahoo.com/news/ceo-ca-presents-pdac-recap-144500076.html
This one could be HUGE 💯
Under-the-radar and extensively oversold (NASDAQ: $HUGE)
Current $0.75
Discover why Shark Tank’s Kevin Harrington Thinks This Underfollowed NASDAQ Company Has a Breakthrough Product that Will CHANGE SOCIETY!
click here >> https://bit.ly/3TDiclf
$RTON Opens 12th Store! This one in “fastest growing county in the country” and “Remains on track to have 25 operating stores by the end of 2024”
https://finance.yahoo.com/news/brands-inc-continues-impressive-rollout-120000600.html
Introducing a new uranium exploration company, Stallion Uranium $STUD $STLNF, focused in the western part of the Athabasca Basin in Saskatchewan.
$TWOH Two Hands Corporation: Elevating Canada's Micro Merchant Wholesaler Landscape https://finance.yahoo.com/news/two-hands-corporation-elevating-canadas-130000053.html
$AURI --SCAM ALERT...see the board
$AURI Token Listing and Partnership With a Top 100 CoinMarketcap Exchange https://www.reddit.com/r/BreakoutStocks/comments/1bdzak7/auri_token_listing_and_partnership_with_a_top_100/
$IFBC #IFBC Dino Luzzi Energy Drink and King #Esport Set to Ignite the Gaming Scene at XMAS COMICS #ESPORTS PARTNERSHIP ENERGIZING DINO LUZZI’S INFLUENCE
Italian Food Beverage Corp. (OTC PINK:IFBC) in its ongoing collaboration with King Esport, has already gained 32.7 million views. The collaboration continued at the gaming event XMAS COMICS, which took place Dec. 17 generating over 35,000 visitors.
The growth of esports, with viewership numbers surpassing those of many traditional sports events, has turned it into a billion-dollar industry, attracting major sponsorships, endorsements and media coverage. https://finance.yahoo.com/news/dino-luzzi-energy-drink-king-140000045.html
$AURI Auri Inc. plans to own and collateralize the gold reserves, and use the added value for its AU, Auri Tokens, as a "gold" backed token. https://www.reddit.com/r/stockstobuytoday/comments/1bdvfq4/auri_huge_buying_opportunity_here/
$AURI announces discussion with Gold Diamond Wawa Property Trust Inc. regarding acquisition/development of the company, including six (6) patented claims in McMurray Township. https://finance.yahoo.com/news/auri-inc-announces-acquisition-gold-170656693.html
$TWOH We're tapping into the pulse of industry trends and statistics, backed by the vision and values laid out at www.twohandsgroup.com. Join us as we explore this strategic pivot, poised to make a significant impact in the retail food sector in Canada! ` https://twohandsgroup.com/blog/twoh-debt-free
#IFBC $IFBC Dino Luzzi Energy Drink and King #Esport Set to Ignite the Gaming Scene at XMAS COMICS #ESPORTS PARTNERSHIP ENERGIZING DINO LUZZI’S INFLUENCE https://finance.yahoo.com/news/dino-luzzi-energy-drink-king-140000045.html
Two Hands Group $TWOH is charting a course towards new horizons.
https://www.reddit.com/r/BreakoutStocks/comments/1bdrvt3/two_hands_group_twoh_is_charting_a_course_towards/
Golden Cross - PRINCESS DIANA’S BROTHER TALKS ABOUT PEDOPHILES AND SADISTS
https://rumble.com/v4it850-princess-dianas-brother-talks-about-pedophiles-and-sadists.html
MAGA NEWS - ELON MUSK IS OFFICIALLY ANNOUNCED AS DONALD TRUMP'S VICE PRESIDENT?
https://rumble.com/v4im39k-3-min-ago-elon-musk-is-officially-announced-as-donald-trumps-vice-president.html
SECRET IS OUT - ELON MUSK SAYS BIDEN PLOT 'FAR WORSE THAN 9/11'
https://rumble.com/v4i0vuo-secret-is-out-elon-musk-says-biden-plot-far-worse-than-911.html
Gold vs M2 Money Supply:
Gold Massively Undervalued vs US Money Supply
$NEWS - Is Gold Setting Up for a Huge, Once in a Generation, Rally?
By Chris Vermeulen
Is there a generational opportunity coming to get into gold?
12 years in the making. $GLD 🥇
— TrendSpider (@TrendSpider) March 3, 2024
Weekly newsletter out tomorrow, sign up for free.
📬 https://t.co/QzvevHvbNs pic.twitter.com/KmlPSJVegT
PDAC 2024: $STLNF Stallion Uranium Commence Maiden Drill Program in SW Athabasca Basin
$STLNF The company holds the largest contiguous project in the Western Athabasca Basin adjacent to multiple high-grade discovery zones.
$IFBC A Ground-Floor Opportunity in a Growing Energy Drink Company
Why this energy drink company could go toe-to-toe with the leaders
https://microcaps.com/a-ground-floor-opportunity-in-a-growing-energy-drink-company/
$STLNF Stallion Uranium Announces Additional Uranium Property Staking, Further Expanding Largest Exploration Land Package in Southwestern Athabasca Basin https://finance.yahoo.com/news/stallion-uranium-announces-additional-uranium-113000019.html
$TWOH STRATEGIC EXPANSION UNVEILED: HOW THE TWOH ACQUISITION PLAYBOOK WILL TRANSFORM FOOD DISTRIBUTION IN CANADA https://twohandsgroup.com/blog/strategic-expansion-twoh-acquisition-playbook
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities
The Company is contemplating a reverse split, if needed to maintain NASDAQ listing compliance, to be accompanied by change in corporate name and CUSIP number
Company has retained former SEC enforcement leadership to notify leading brokerages of the need to close all naked short positions in the Company's securities and to prevent future accumulation of naked short positions in the Company's new security
RADNOR, Pa., March 12, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company" today initiated actions to combat short sellers in the Company's stock.
The Company announced a proposal to simultaneously change the CUSIP under which the Company's shares are traded, together with changing the name of the Company to NRx Therapeutics, Inc. The Company plans to accompany these actions with a required exchange of the underlying stock certificates. This certificate change is expected to be seamless for those investors holding NRXP shares in electronic form and similarly for investors who may have established short positions in NRXP by borrowing the underlying shares from a registered shareholder. Any party holding a short position in the Company's shares who has not complied with the legal requirement to borrow the underlying shares of stock (i.e. "a naked short" may be unable to exchange that position for a position in the new security.
The Company is working with attorneys who formerly served in leadership positions at the SEC Division of Enforcement to correspond with corporate counsel and compliance heads at leading brokerages to emphasize the current legal prohibitions against naked short sales. As identified in previous announcements, the Company was advised by ShareIntel in September 2023 that substantial naked short positions in the Company's securities had been identified at major brokerage firms.
"We believe it is in the best interests of our shareholders to have fully-compliant trading in the markets," said Janet Rehnquist, Esq., who chairs the Company's Compliance Committee. "As we focus on the development of potentially life-saving drugs to combat suicidal depression, PTSD, and Chronic Pain, it is critical that we take all steps possible to maximize the value of those who have invested in our Company and provided the resources to address these critical unmet medical needs."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-initiates-strategy-to-combat-short-sales-302086668.html
SOURCE NRx Pharmaceuticals, Inc.
REI......TELL......DUO.........................https://stockcharts.com/h-sc/ui?s=DUO&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=TELL&p=W&b=5&g=0&id=p84354014936
https://stockcharts.com/h-sc/ui?s=REI&p=W&b=5&g=0&id=p84354014936
$NRXP: NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
Company to receive first allocation of ketamine for sale by month end
Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies
NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply
Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely reimbursed, solution for patients and clinics, subject to board approval
RADNOR, Pa., March 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") and its wholly owned subsidiary HOPE Therapeutics, clinical-stage biopharmaceutical companies, today announced completion of a Memorandum of Understanding with Conversio Health, a national 503a pharmacy, and a strong, ongoing partnership with Nephron Pharmaceuticals, a manufacturer of Ketamine and 503b pharmacy to provide IV Ketamine to patients and clinics across the country, subject to board approval. These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.
(PRNewsfoto/NRx Pharmaceuticals)
(PRNewsfoto/NRx Pharmaceuticals)
The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized. Details for ordering will be available on our website as soon as they are available. www.hopetherapeutics.com
In contrast to NRx Pharmaceuticals, which is structured as a Biotechnology research and development company, HOPE Therapeutics is structured as a Specialty Pharmaceutical company that aims to supply a variety of therapeutic products to clinics that are treating suicidal depression and PTSD, including both traditional and digital therapeutics.
"We are pleased to be working with two outstanding organizations in Conversio Health and Nephron Pharmaceuticals to provide this important medication to a market in need of a consistent supply of high-quality, FDA- and DEA- compliant IV ketamine," said Matthew Duffy Chief Business Officer of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics. "Importantly, these efforts will provide a strong foundation for expanding our product offering with our planed filing a New Drug Application with the FDA in the coming months, and the potential launch of HTX-100 in early 2025." The NDA filing currently awaits completion of an additional three months of product stability.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through HOPE Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-completes-memorandum-of-understanding-and-collaborations-with-distribution-partners-for-htx-100-iv-ketamine-302085271.html
SOURCE NRx Pharmaceuticals, Inc.
IHRT.........REI.............TELL..........................https://stockcharts.com/h-sc/ui?s=IHRTx&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=REI&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=TELL&p=D&yr=0&mn=3&dy=0&id=p11960084343
SONX... Here's what the excitement is about..... Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.
Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.
An archived recording will be available on the “Investors” section of the company’s website at: https://investor.sonendo.com. The webcasts will be available for replay for at least 90 days after the event.
$LBRG Undervalued Here! Ladybug Analyst Price Target Average 0.0561 (+274.09% Upside)
https://stockscan.io/stocks/LBRG
The recorded, final version of the **CBS news covering IFUS tonight is out. It was recorded**. The Text version has a link the front page of the IFUS website that features the SGP+(tm) game changer cattle feed. The story is about IFUS SGP+(tm) cattle feed donation to the North Texas cattle owners to help save what is left of their cattle, and the fact that this new super low cost game changer cattle feed is a huge solution to climate change driven disasters like North Texas suffered last week, that destroyed 1.1 Million acres of grass and cattle industry assets.
https://www.wafb.com/2024/03/07/new-innovative-cattle-feed-being-donated-north-texas/
MULN........................................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936
$LBRG Acquisitions have diversified revenue streams bringing revenues to almost $6million/Yr !!!
The recent acquisition of Nutra55 is expected to boost revenue by $2.4 million! https://stocktitan.net/news/LBRG/ladybug-announces-acquisition-of-e-commerce-generating-2-4-million-ot3u2ufjcdf0.html
$CBDW Perfect entry zone here @0.03 https://schrts.co/ezqjwGga
$SYNX is proud to announce that it has developed an innovative new product designed for dogs in militaries. https://www.silynxcom.com/silynxcom-unveils-groundbreaking-headset-for-military-dogs-offering-unparalleled-protection-and-communication/
LWLG making internet go faster using less energy
Thats what data centers need
LWLG BUY RATING
LWLG MAKING INTERNET FASTER WITH LESS ENERGY
https://www.lightwavelogic.com/
http://www.washingtonpost.com/business/2024/03/07/ai-data-centers-power/
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=LWLG
SONX....GAME CHANGER **** Sonendo, Inc... conference call for the Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
March 1, 2024
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Sonendo, Inc. (“Sonendo”) (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.
Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.
$LBRG Ladybug NutraTech's strategic rebranding is underscored by the unveiling of its new website, http://ladybugnutratech.com, marking a significant evolution in the company's business strategy.
$NRXP News: NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression
The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter
Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported.
Positive data and FDA comment would trigger the next $4 million milestone payment from partners Alvogen and Lotus and their assumption of development costs; agreement provides for up to $329 million in milestone payments and a royalty on Net Sales in the mid-teens
RADNOR, Pa., March 4, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The database is being cleaned, finalized, and locked; statistical analysis will then be performed, with top-line data to follow shortly thereafter. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.
NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.
"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "
The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.
Top-line results are expected around the end of this quarter.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL51263&sd=2024-03-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html
SOURCE NRx Pharmaceuticals, Inc.
$LBRG through its subsidiary Growhouse Nutraceuticals Ltd., is actively bolstering its revenue with strategic acquisitions in the health and wellness domain.https://www.reddit.com/r/10xPennyStocks/comments/1b7923j/ladybug_lbrg_announces_acquisition_of_ecommerce/
Silynxcom Ltd (NYSE- Amer: $SYNX) stock is continuing its bullish ways
https://reddit.com/r/stockstobuytoday/comments/1b83ijm/silynxcom_ltd_nyse_amer_synx_stock_is_continuing/
Followers
|
1527
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
84153
|
Created
|
03/06/15
|
Type
|
Free
|
Moderator PennyMaster | |||
Assistants Golden Cross hstang04 Garyst BLULLISH |
*DISCLAIMER*
•The Board Moderator and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• Always do your own due diligence with any stock you may consider buying and never invest more than you are willing to lose.
• Stocks mentioned here may or may not be held by members posting on this board.
• There are no guarantees when buying or selling any security.
Posts Today
|
0
|
Posts (Total)
|
84153
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |